Health Care & Life Sciences » Pharmaceuticals | Neos Therapeutics Inc.

Neos Therapeutics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2015
2016
2017
2018
Net Income before Extraordinaries
30,781.00
83,333.00
66,247.00
51,675
Depreciation, Depletion & Amortization
3,242.00
3,260.00
3,023.00
3,487
Other Funds
-
415.00
40.00
3,812
Funds from Operations
24,775.00
71,582.00
56,495.00
44,376
Changes in Working Capital
1,092.00
936.00
3,234.00
2,935
Net Operating Cash Flow
25,867.00
70,646.00
53,261.00
41,441
Capital Expenditures
1,023.00
4,050.00
2,858.00
Sale of Fixed Assets & Businesses
-
-
3,222.00
Purchase/Sale of Investments
3,000.00
15,272.00
2,897.00
Net Investing Cash Flow
1,977.00
19,322.00
2,533.00
Issuance/Reduction of Debt, Net
8,346.00
23,190.00
989.00
Net Financing Cash Flow
101,310.00
23,557.00
63,411.00
Net Change in Cash
77,420.00
66,411.00
7,617.00
Free Cash Flow
26,890.00
74,196.00
55,758.00
Change in Capital Stock
92,964.00
48.00
64,440.00

About Neos Therapeutics

View Profile
Address
2940 North Highway 360
Grand Prairie Texas 75050
United States
Employees -
Website http://www.neostx.com
Updated 07/08/2019
Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold.